Insider Transactions At Editas Medicine

Editas Medicine, Inc. ( NASDAQ:EDIT ) President Gilmore O’Neill recently offloaded about US$733k of stock at an average price of US$9.42 in an automated tax sale. That sale reduced their total holding by 45%.

See our latest analysis for Editas Medicine

The Last 12 Months Of Insider Transactions At Editas Medicine

In fact, the recent sale by Gilmore O’Neill was the biggest sale of Editas Medicine shares made by an insider individual in the last twelve months, according to our records. 

In the last year Editas Medicine insiders didn't buy any company stock. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. By clicking on the graph below, you can see the precise details of each insider transaction!

For those who like to find winning investments this free list of growing companies with recent insider purchasing, could be just the ticket.

Insider Ownership Of Editas Medicine

I like to look at how many shares insiders own in a company, to help inform my view of how aligned they are with insiders. Usually, the higher the insider ownership, the more likely it is that insiders will be incentivised to build the company for the long term. Based on our data, Editas Medicine insiders have about 0.3% of the stock, worth approximately US$2.3m. I generally like to see higher levels of ownership.

What Might The Insider Transactions At Editas Medicine Tell Us?

Insiders sold Editas Medicine shares recently, but they didn't buy any. Looking to the last twelve months, our data doesn't show any insider buying. Insiders own relatively few shares in the company, so we're not particularly excited about the stock. We'd certainly practice some caution before buying! In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing Editas Medicine. Case in point: We've spotted 4 warning signs for Editas Medicine you should be aware of.

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.